HVEM

BITT Provides Update on DOMab Platform and CD40 Program

Retrieved on: 
Monday, February 13, 2023
Oncology, Health, Infectious Diseases, Research, Science, Pharmaceutical, Biotechnology, CD40, Toxicology, Dam, CD27, Lupus, TNF, Rheumatoid arthritis, Inflammatory bowel disease, OX40, File, Entrepreneurship, Inflammation, HVEM, Cell death, Therapy, Autoimmunity, Antibody, TNFR2, Multiple sclerosis, TRAIL, Psoriasis, IND, Vaccine

Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today updates on the company’s DOMab™ platform.

Key Points: 
  • Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel tumor necrosis factor superfamily receptor (TNFSR) antagonist antibodies, announced today updates on the company’s DOMab™ platform.
  • Two DOMab CD40 antagonists (BITT-CD4D11 and BITT-CD4F10) have completed discovery and optimization and a final candidate is being selected for IND-enabling steps.
  • “The development of dominant antibodies to our second TNF superfamily target is a major validation for the DOMab platform,” said Russell LaMontagne, Co-Founder and Chief Executive Officer of BITT.
  • “We will be presenting preclinical data from both the CD40 and TNFR2 programs at conferences in the first half of 2023.”
    BITT’s DOMab antibodies create unique surface stabilization of anti-parallel dimers for altering intracellular signaling.

HiFiBiO Therapeutics Receives FDA Clearance of IND Application for HFB200603

Retrieved on: 
Friday, January 6, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, CSO, Investigational New Drug, PD-1, Food, BTLA, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, HVEM, Tislelizumab, Neoplasm, Patient, Tumor microenvironment, Lymphocyte, FDA, Vaccine, Pharmaceutical industry, IND

HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603.

Key Points: 
  • HiFiBiO Therapeutics, a multinational clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for HFB200603.
  • HFB200603 is a novel monoclonal antibody against the immune checkpoint BTLA that blocks the interaction with its ligand, HVEM.
  • HFB200603 is designed to reverse HVEM-mediated immune suppressive effects and induce the production of inflammatory cytokines in various solid tumors selected by HiFiBiO’s proprietary Drug Intelligence Science (DIS™) platform.
  • HFB200603 synergizes with anti-PD-1 and demonstrates favorable developability, pharmacokinetic and safety profiles.

Junshi Biosciences Announces Updated Clinical data from Phase I study of anti-BTLA antibody Tifcemalimab in Treatment of Relapsed/Refractory Lymphomas at 64th ASH Annual Meeting

Retrieved on: 
Saturday, December 10, 2022
Neoplasm, SD, Marketing, ASH, DCR, B-cell lymphoma, American Society of Clinical Oncology, Research, Junshi, COVID-19, Lilly, NMPA, Clinical trial, Oncology, FDA, Lymphoma, Safety, Bamlanivimab, Cancer, PD-1, Social responsibility, Immunoglobulin superfamily, Dor, DLT, Society, CD28, Hodgkin lymphoma, HL, ASCO, TNF, ORR, Bamlanivimab/etesevimab, Ira Pastan, NHL, SSE, Development, Patient, Time-invariant system, HVEM, Poster, Microbiology, BTLA, EUA, HKEX, Lymphocyte, Infection, Autoimmunity, Severe acute respiratory syndrome coronavirus 2, Pharmaceutical industry, Vaccine, Medical imaging, Science, Chinese, Hematology

SHANGHAI, China, Dec. 10, 2022 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the updated preliminary data from a Phase I study of tifcemalimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas in a poster at the 64th American Society of Hematology (ASH) Annual Meeting. Tifcemalimab is the world’s first-in-human anti-tumor anti-BTLA monoclonal antibody independently developed by the company.

Key Points: 
  • The observed clinical activity of tifcemalimab in combination with toripalimab in lymphoma patients refractory to checkpoint inhibitors warrants further evaluation.
  • “However, if PD-1 inhibitors fail, there is no standard treatment to resort to, thus new treatment methods are urgently needed in clinical practice.
  • This is the very first time an anti-BTLA antibody was evaluated for safety and efficacy in the treatment of lymphomas.
  • Now, updated results from the clinical trial for lymphomas have been presented at the ASH annual meeting.

HiFiBiO Therapeutics Announces Clinical Trial Supply Agreement to Evaluate HFB200603 in Combination with Tislelizumab in Patients with DIS™ Selected Advanced Solid Tumors

Retrieved on: 
Friday, November 18, 2022
Research, Genetics, Clinical Trials, Health Technology, Biotechnology, Health, Pharmaceutical, Science, Oncology, Clinical trial, DIS, Therapy, PD-1, Cancer, Macrophage, Degenerative disease, HVEM, Tumor microenvironment, Immunology, Immunoglobulin G, Tislelizumab, BTLA, Drug discovery, Novartis, Patient, Antibody, Pharmaceutical industry, Medical device, Vaccine

Under the terms of the agreement, HiFiBiO Therapeutics will maintain control of the HFB200603 program, including global R&D and commercial rights.

Key Points: 
  • Under the terms of the agreement, HiFiBiO Therapeutics will maintain control of the HFB200603 program, including global R&D and commercial rights.
  • Novartis has agreed to supply tislelizumab for use in combination with HFB200603.
  • HiFiBiO Therapeutics is a clinical stage biotech company advancing a robust pipeline targeting both the innate and adaptive immunity to treat cancer and autoimmune diseases.
  • www.hifibio.com
    HiFiBiO Therapeutics, HiFiBiO Therapeutics logo, and DIS are trademarks of HiFiBiO and its affiliates.

Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million

Retrieved on: 
Monday, November 7, 2022
HVEM, Company, Private Securities Litigation Reform Act, TNFRSF3, Therapy, LLC, CD160, Sale, BTLA, Armistice, TNFRSF14, Board, End-user license agreement, GLOBE, HSV, Safety, TNFSF14, COVID-19, Janssen Pharmaceuticals, Asset purchase agreement, Nasdaq, ES, Herpesvirus entry mediator, PEAK, Forward-looking statement, Inflammatory Bowel Diseases, Drug development, License, Assignment, NEA, SEC, Autoimmunity, Patient, MD, Pharmaceutical industry, Vaccine

Once completed, we will have raised $20 million of nondilutive funding since August.

Key Points: 
  • Once completed, we will have raised $20 million of nondilutive funding since August.
  • The purchase agreement contains customary representations and warranties and covenants of the Company and ES.
  • Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network.
  • ES Therapeutics is a privately held global pharmaceutical company focused on the development of therapeutics to treat certain neurological disorders.

Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage

Retrieved on: 
Tuesday, September 6, 2022
Sanford Burnham Prebys Medical Discovery Institute, CA, COVID-19, Inflammation, Safety, HVEM, IND, TNFRSF14, Therapy, NASDAQ, Autoimmunity, TNFRSF3, Board, Director, Lead, Asthma, HSV, SEC, Patent, MD, GLOBE, BTLA, Immune system, Attention, PEAK, Inflammatory Bowel Diseases, TNFSF14, Herpesvirus entry mediator, NEA, Hector Avalos, Private Securities Litigation Reform Act, CD160, Drug development, Forward-looking statement, Patient, Vaccine, Pharmaceutical industry

In June 2021, Avaloacquired rights to the BTLA fusion protein technology discovered by Dr. Carl Ware and colleagues at the Sanford Burnham Prebys in La Jolla, CA.

Key Points: 
  • In June 2021, Avaloacquired rights to the BTLA fusion protein technology discovered by Dr. Carl Ware and colleagues at the Sanford Burnham Prebys in La Jolla, CA.
  • Avalo is becoming a world-leader through our collaboration with Dr. Ware in this field with two high quality biologic drug candidates that address critical components of the LIGHT-signaling network.
  • AVTX-008 is a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.
  • Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT network.

Avalo to Present at the H.C. Wainwright Global Investment Conference

Retrieved on: 
Thursday, September 1, 2022
COVID-19, HVEM, TNFRSF14, Therapy, Autoimmunity, Board, HSV, SEC, GLOBE, Conference, BTLA, Nasdaq, TNFSF14, Investor, Herpesvirus entry mediator, Private Securities Litigation Reform Act, CD160, Drug development, Forward-looking statement, Patient, Pharmaceutical industry

WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.

Key Points: 
  • WAYNE, Pa. and ROCKVILLE, Md., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held September 12-14, 2022.
  • The pre-recorded formal presentation will be made available on Monday, September 12, 2022 at 7:00 AM ET.
  • A webcast of the pre-recorded presentation can be accessed under the News/Events page in the Investors section of the Companys website, www.avalotx.com .
  • Avalo Therapeutics is a clinical stage biotechnology company focused on the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network.

AnaptysBio Announces Positive ANB032 (anti-BTLA agonist) Top-Line Phase 1 Data and Provides Pipeline Updates

Retrieved on: 
Wednesday, April 27, 2022
CPK, Cell, Security (finance), GSK, Safety, Bruise, SAD, Șaeș, HVEM, GLOBE, IND, Degenerative disease, AST, Goal, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Toxic epidermal necrolysis, Inflammation, Forward-looking statement, GPP, COVID, Immune system, BTLA, Nasdaq, Erythema, Pain, TRADD, Human, MAD, SAN, SHM, Pharmaceutical industry, Vaccine

We believeANB032smechanism is broadly applicable to Tand Bcell driven inflammatory diseases and look forward to further clinical developmentwith this important immune checkpointmodulator.

Key Points: 
  • We believeANB032smechanism is broadly applicable to Tand Bcell driven inflammatory diseases and look forward to further clinical developmentwith this important immune checkpointmodulator.
  • Most adverse events were considered to be mild-to-moderate, of short duration, resolved without sequelae and occurred sporadically in a dose-independent manner.
  • Pharmacokinetic analyses demonstrated a favorable profile for ANB032 including an approximate two-weekhalf-lifefor subcutaneous and intravenous routes of administration.
  • Based upon these data, we believe ANB032s in vivo mechanism has the potential to broadly treat T and B-cell driven human inflammatory diseases.

Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Cytokine, FC, CD20, NASDAQ, Lymphoma, CD47, Mouse, AACR, Poster, American Association, TGF beta signaling pathway, Cancer, PD-1, Autoimmune disease, ARC, TNF, Association, HVEM, TIGIT, PVR, CD19, GLOBE, Myelocyte, Primate, BTN3A1, Patient, Vaccine, Medical imaging, CD40

AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform, and the company’s GADLEN platform.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
  • This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the companys ARC platform, and the companys GADLEN platform.
  • We have made excellent progress advancing compounds in our preclinical pipeline, said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • Together, these results suggest that TIGIT-Fc-LIGHT may provide clinical benefit to patients that are refractory to conventional checkpoint blockade therapy.

DGAP-News: Apogenix Receives EUR 20.7 Million in Public Funding for Pivotal Study and Preparation for Market Production of Asunercept for the Treatment of COVID-19

Retrieved on: 
Thursday, December 9, 2021
FC, GITR, BMG, HERA, Interim, CD40, TRAIL, Population, PEI, Investor, CD95, Immunotherapy, BMBF, AbbVie, Disease, Paul Ehrlich Institute, HVEM, CD27, Oxygen, Death, Acute respiratory distress syndrome, TNF, Patient, Acute myeloid leukemia, Asunercept, Lymphatic system, Cancer, II, Vaccination, COVID-19 vaccine, Government, GMP, Education, Priority, European Medicines Agency, COVID-19, MDS, Degenerative disease, Immunoglobulin G, B-cell lymphoma, PRIME, Glioblastoma, Microdeletion syndrome, III, Lymphocytopenia, National Institute of Pharmaceutical Education and Research, Hajipur, Pharmaceutical industry

In addition, the GMP production process for asunercept will be further developed to market maturity and the required material for the phase III clinical trial will be produced.

Key Points: 
  • In addition, the GMP production process for asunercept will be further developed to market maturity and the required material for the phase III clinical trial will be produced.
  • By directly targeting two critical pathogenic mechanisms, asunercept could represent a unique therapeutic approach for the treatment of COVID-19.
  • Apogenix is a private company developing innovative immunotherapeutics for the treatment of cancer and viral infections, such as COVID-19.
  • Asunercept is exclusively licensed to CANbridge Life Sciences under a development and commercialization license covering China, Macao, Hong Kong, and Taiwan.